Ishmeala Rigby

Ishmeala Rigby

Auto-generated profile, based on publicly available information

Ishmeala Rigby

International Severe Acute Respiratory and Emerging Infection Consortium, Pandemic Sciences Institute, University of Oxford, Oxford, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2022 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
EWEika Webb
Eika Webb
IRIshmeala Rigby
Ishmeala Rigby
MMMelina Michelen
Melina Michelen
ADAndrew Dagens
Andrew Dagens
VCVincent Cheng
Vincent Cheng
PHPeter W Horby
Peter W Horby
Background Monkeypox (MPX) is an important human Orthopoxvirus infection. There has been an increase in MPX cases and outbreaks in endemic and non-endemic regions in recent decades. We appraised the availability, scope, quality and inclusivity of clinical management guidelines for MPX globally. Methods For this systematic review, we searched six databases from inception until 14 October 2021, augmented by a grey literature search until 17 May 2022. MPX guidelines providing treatment and supportive care recommendations were included, with no exclusions for language. Two reviewers assessed the guidelines. Quality was assessed using the Appraisal of Guidelines for Research and Evaluation II tool. Results Of 2026 records screened, 14 guidelines were included. Overall, most guidelines were of low-quality with a median score of 2 out of 7 (range: 1–7), lacked detail and covered a narrow range of topics. Most guidelines focused on adults, five (36%) provided some advice for children, three (21%) for pregnant women and three (21%) for people living with HIV. Treatment guidance was mostly limited to advice on antivirals; seven guidelines advised cidofovir (four specified for severe MPX only); 29% (4/14) tecovirimat, and 7% (1/14) brincidofovir. Only one guideline provided recommendations on supportive care and treatment of complications. All guidelines recommended vaccination as post-exposure prophylaxis (PEP). Three guidelines advised on vaccinia immune globulin as PEP for severe cases in people with immunosuppression. Conclusion Our results highlight a lack of evidence-based clinical management guidelines for MPX globally. There is a clear and urgent need for research into treatment and prophylaxis including for different risk populations. The current outbreak provides an opportunity to accelerate this research through coordinated high-quality studies. New evidence should be incorporated into globally accessible guidelines, to benefit patient and epidemic outcomes. A ‘living guideline’ framework is recommended. PROSPERO registration number CRD42020167361.

6 February 2023 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
IRIshmeala Rigby
Ishmeala Rigby
MMMelina Michelen
Melina Michelen
ADAndrew Dagens
Andrew Dagens
VCVincent Cheng
Vincent Cheng
DDDania Dahmash
Dania Dahmash
LSLouise Sigfrid
Louise Sigfrid

7 November 2022 in BMC Medicine
Verified
Journal Article
Open access
PDF file
IRIshmeala Rigby
Ishmeala Rigby
MMMelina Michelen
Melina Michelen
VCVincent Cheng
Vincent Cheng
ADAndrew Dagens
Andrew Dagens
DDDania Dahmash
Dania Dahmash
LSLouise Sigfrid
Louise Sigfrid
Background: The COVID-19 pandemic has highlighted the importance of evidence-based clinical decision-making. Clinical management guidelines (CMGs) may help reduce morbidity and mortality by improving the quality of clinical decisions. This systematic review aims to evaluate the availability, inclusivity, and quality of pandemic influenza CMGs, to identify gaps that can be addressed to strengthen pandemic preparedness in this area. Methods: Ovid Medline, Ovid Embase, TRIP (Turning Research Into Practice), and Guideline Central were searched systematically from January 2008 to 23rd June 2022, complemented by a grey literature search till 16th June 2022. Pandemic influenza CMGs including supportive care or empirical treatment recommendations were included. Two reviewers independently extracted data from the included studies and assessed their quality using AGREE II (Appraisal of Guidelines for Research & Evaluation). The findings are presented narratively. Results: Forty-eight CMGs were included. They were produced in high- (42%, 20/48), upper-middle- (40%, 19/48), and lower-middle (8%, 4/48) income countries, or by international organisations (10%, 5/48). Most CMGs (81%, 39/48) were over 5 years old. Guidelines included treatment recommendations for children (75%, 36/48), pregnant women (54%, 26/48), people with immunosuppression (33%, 16/48), and older adults (29%, 14/48). Many CMGs were of low quality (median overall score: 3 out of 7 (range 1–7). All recommended oseltamivir; recommendations for other neuraminidase inhibitors and supportive care were limited and at times contradictory. Only 56% (27/48) and 27% (13/48) addressed oxygen and fluid therapy, respectively. Conclusions: Our data highlights the limited availability of up-to-date pandemic influenza CMGs globally. Of those identified, many were limited in scope and quality and several lacked recommendations for specific at-risk populations. Recommendations on supportive care, the mainstay of treatment, were limited and heterogeneous. The most recent guideline highlighted that the evidence-base to support antiviral treatment recommendations is still limited. There is an urgent need for trials into treatment and supportive care strategies including for different risk populations. New evidence should be incorporated into globally accessible guidelines, to benefit patient outcomes. A ‘living guideline’ framework is recommended and further research into guideline implementation in different resourced settings, particularly low- and middle-income countries.

27 August 2021 in F1000Research
Verified
Journal Article
Open access
PDF file
MMMelina Michelen
Melina Michelen
VCVincent Cheng
Vincent Cheng
LMLakshmi Manoharan
Lakshmi Manoharan
NENatalie Elkheir
Natalie Elkheir
DDDrew Dagens
Drew Dagens
CSCharitini Stavropoulou
Charitini Stavropoulou
Although the majority of people with Covid-19 will experience mild to moderate symptoms and will recover fully, there is now increasing evidence that a significant proportion will experience persistent symptoms for months after the acute phase of the illness. These symptoms include, among others, fatigue, problems breathing, lack of smell and taste, headaches, and depression and anxiety. It is also clear the virus has lasting fluctuating multiorgan sequelae, including affecting not only the respiratory system but also the heart, liver, and nervous system. We present a protocol for a living systematic review that aims to synthesize the evidence on the prevalence and characteristics of post-acute COVID-19. The living systematic review will be updated regularly, approximately every 6 months, as new evidence emerges. We will include studies that follow up at least 100 people with Covid-19 at 12 or more weeks post Covid-19 onset, with no restrictions regarding country, setting, or language. We will use descriptive statistics and, for outcomes reported in two or more studies, we will use meta-analyses to estimate prevalence with 95% confidence intervals (CIs) using the exact method. Heterogeneity between estimates will be assessed using the I2 statistic. Our findings will also be presented as infographics to facilitate transcription to lay audiences. Ultimately, we aim to support the work of policy makers, practitioners, and patients when planning rehabilitation for those recovering from Covid-19. The protocol has been registered with PROSPERO ( CRD42020211131, 25/09/2020).

15 January 2021 in medRxiv
Verified
Preprint
Open access
PDF file
SLSamuel Lipworth
Samuel Lipworth
IRIshmeala Rigby
Ishmeala Rigby
VCVincent Cheng
Vincent Cheng
PBPeter Bannister
Peter Bannister
EHEli Harriss
Eli Harriss
PHPeter Horby
Peter Horby
Objective: To assess the responsiveness and quality of clinical management guidelines (CMGs) in SARS, MERS and COVID-19 and determine whether this has improved over time. Design: Rapid literature review, quality assessment and focus group consultation. Data Sources: – Google and Google Scholar were systematically searched from inception to 6 th June 2020.This was supplemented with hand searches of national and international public health agency and infectious disease society websites as well as directly approaching clinical networks in regions where few CMGs had been identified via the primary search. Eligibility Criteria: CMGs for the treatment of COVID-19/SARS/MERS providing recommendations on supportive care and/or specific treatment. Methods: Data extraction was performed using a standardised form. The Appraisal of Guidelines for Research and Evaluation (AGREE-II) tool was used to evaluate the quality of the CMGs. Six COVID-19 treatments were selected to assess the responsiveness of a subset of guidelines and their updates to 20 th November 2020. We ran two sessions of focus groups with patient advocates to elicit their views on guideline development. Results: We included 37 COVID-19, six SARS, and four MERS CMGs. Evidence appraisals in CMGs generally focused on novel drugs rather than basic supportive care; where evidence for the latter was provided it was generally of a low quality. Most CMGs had major methodological flaws (only two MERS-CoV and four COVID-19 CMGs were recommended for use by both reviewers without modification) and there was no evidence of improvement in quality over time. CMGs scored lowest in the following AGREE-II domains: scope and purpose, editorial independence, stakeholder engagement, and rigour of development. Of the COVID-19 CMGs, only eight included specific guidance for the management of elderly patients and only ten for high-risk groups; a further eight did not specify the target patient group at all. Early in the pandemic, multiple guidelines recommended unproven treatments and whilst in general findings of major clinical trials were eventually adopted, this was not universally the case. Eight guidelines recommended that use of unproven agents should be considered on a case-by-case basis. Patient representatives expressed concern about the lack of engagement with them in CMG development and that these documents are not accessible to non-experts. Conclusion: The quality of most CMGs produced in coronaviridae outbreaks is poor and we have found no evidence of improvement over time, highlighting that current development frameworks must be improved. There is an need to strengthen the evidence base surrounding basic supportive care and develop methods to engage patients in CMG development from the beginning in outbreak settings. Systematic review registration: PROSPERO CRD42020167361

21 November 2024 in medRxiv
Verified
Preprint
Open access
PDF file
DDDania Talaat Dahmash
Dania Talaat Dahmash
MMMelina Michelen
Melina Michelen
IRIshmeala Rigby
Ishmeala Rigby
HPHelen Piotrowski Piotrowski
Helen Piotrowski Piotrowski
RNRobert Nartowski
Robert Nartowski
LSLouise Sigfrid
Louise Sigfrid
Background: High consequence infectious disease (HCID) outbreaks are a threat to societies globally. Evidence-based clinical management guidelines (CMGs) are important tools for translating evidence into clinical practice. However, developing guidelines is resource-intensive and guidelines must remain responsive to new evidence while being accessible to clinicians. This review aims to identify factors that impact the implementation of HCID CMGs across different contexts during health emergencies. Methods: A systematic review. Four databases (Ovid MEDLINE, Ovid Embase, Ovid Global Health, and Scopus) were searched until November 2021, complemented by a grey literature search conducted on November 2021. Studies that explored implementation of HCID guidelines were included, without language restriction. Two reviewers screened articles and extracted data. Data was analysed using qualitative inductive thematic analysis. Results: Of 12,512 records, 28 studies were included, with most (61%, 17/28) set in high-income countries. Three overarching themes impacting HCID CMG implementation were identified: 1) Development and characteristics of CMGs, 2) Organisational and logistical factors, and 3) Realities of Implementing guidelines. Key recommendations included engaging all relevant representatives in CMG development, including those in endemic countries; integrating mechanisms for regular updates; supporting implementation by ensuring access to necessary resources (e.g., equipment, pharmaceuticals), and training; and enabling intra- and inter-organisational collaboration and communication channels. Importantly, recognising the challenges faced by staff in implementing new guidance is crucial, as is understanding the impact of a supportive environment on the effective implementation of care during emergencies. Conclusion: These findings highlight the need to bridge the gap between HCID CMGs development and their real-world implementation amid health emergencies. The complex factors impacting effective implementation should be addressed beginning at the development stage, with training focused on implementation during inter-epidemic times, and ongoing implementation monitored during outbreaks. Further research to guide implementation frameworks are recommended. Key messages of the article: What is already known on this topic: - Clinical management guidelines (CMGs) are important tools to guide clinical decision-making and optimise care and outcome. - The COVID-19 pandemic showcased the need for CMGs to be rapidly responsive to new emerging evidence. - HCID CMGs are scarce and often of low quality, and when available they frequently contain inconsistent therapeutic recommendations. - Most CMGs are developed by high-income countries while the burden is often the largest in resource deprived settings. What this study adds: - This study highlights the gap between HCID CMGs development and their implementation in real world within emergency setting. - The review explores the potential factors that influence the implementation process of HCID CMGs such as time, information and resource constraints. - Key recommendations to stakeholder and CMGs developers were explored within this study such as the use of “living guidelines” to make CMGs updates more efficient, and the availability of viable alternative options for different-resourced healthcare settings to bridge the gap between the ideal situation and the local realities. - There is a need for a clear communication and consensus on HCP expectations and obligations during health emergencies within CMGs as well as the practicalities of delivering training during emergencies need to be addressed within CMG development and implementation. How this study might affect research, practice or policy: - HCID implementation research should consider these factors impacting effective implementation when planning, from the development stage through ongoing monitoring. - Further research and funds are needed to guide implementation frameworks.